Skip to main content
SpringerLink
Log in

Anti-Adrenergic Therapy in Hypertensive Patients with Concomitant Disease

  • Conference paper
Prevention of Disease Progression Throughout the Cardiovascular Continuum

  • 64 Accesses

Abstract

The importance of hypertension as a risk factor for heart failure [1, 2] reinforces the importance of preventative strategies directed towards earlier and more aggressive blood pressure control. Treatment of hypertension has been shown to improve outcomes in hypertensive subjects, particularly when the agent used not only controls blood pressure but also limits or reverses myocardial hypertrophy [2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure (JNC V) [published erratum appears in Arch Intern Med 1998; 158: 573]. Arch Intern Med 1997; 157: 2413–46.

    Article  Google Scholar 

  2. Deedwania PC. The progression from hypertension to heart failure. Am J Hypertens 1997; 10: 280S–288S.

    Article  PubMed  CAS  Google Scholar 

  3. Ho KK, Pinsky JL, Kannel WB et al. The epidemiology of heart failure: the Framingham Study. J Am Call Cardiol 1993; 22 (4 Suppl A): 6A–13A.

    Article  CAS  Google Scholar 

  4. Dzau VJ, Braunwald E. Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement. Am Heart J 1991; 121: 1244–63.

    Article  PubMed  CAS  Google Scholar 

  5. Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J 1991; 121: 951–7.

    Article  PubMed  CAS  Google Scholar 

  6. Prichard BNC, Gillam PMS. Use of propranolol (Inderal) in treatment of hypertension. BMJ 1964; 2: 725–7.

    Article  PubMed  CAS  Google Scholar 

  7. Levy D, Larson MG, Vasan RS et al. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557–62.

    Article  PubMed  CAS  Google Scholar 

  8. Bourassa MG, Gurne O, Bangdiwala SI et al. Natural history and patterns of current practice in heart failure. The Studies of Left Ventricular Dysfunction (SOLVD) Investigators. J Am Coll Cardiol 1993; 22 (4 Suppl A): 14A–19A.

    Article  PubMed  CAS  Google Scholar 

  9. Birkenhager WH, de Leeuw PW. Determining hypertensive end-organ damage in trials: a review of current methodologies and techniques. J Cardiovasc Pharmacol 1992; 19(5uppl 5): S43–S50.

    PubMed  Google Scholar 

  10. Veterans Administration Cooperative Study Group. Effects of treatment on morbidity in hypertension II. JAMA 1970; 213: 1143–52.

    Article  Google Scholar 

  11. Burt VL, Culter JA, Higgins M et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991 [published erratum appears in Hypertension dy1996; 27(5): 1192]. Hypertension 1995; 26: 60–9.

    Article  PubMed  CAS  Google Scholar 

  12. Guerrero-Romero JF, Alvarado-Ruiz R, Rodriguez-Moran M. Accumulated probability of hypertension in diabetes and of diabetes in hypertension. Rev Invest Clin 1998; 50: 281–5.

    PubMed  CAS  Google Scholar 

  13. Escobedo-de-la-Pena J, Islas S, Lifshitz-Guinzberg A et al. Higher prevalence of diabetes in hypertensive subjects with upper body fat distribution. Rev Invest Clin 1998; 50: 5–12.

    PubMed  CAS  Google Scholar 

  14. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979; 241: 2035–8.

    Article  PubMed  CAS  Google Scholar 

  15. Chen YT, Vaccarino V, Williams CS et al. Risk factors for heart failure in the elderly: a prospective community-based study. Am J Med 1999; 106: 605–12.

    Article  PubMed  CAS  Google Scholar 

  16. Krumholz HM, Chen YT, Wang Y et al. Predictors of readmission among elderly survivors of admission with heart failure. Am Heart J 2000; 139: 72–7.

    Article  PubMed  CAS  Google Scholar 

  17. Kannel WB, Levy D, Cupples LA. Left ventricular hypertrophy and risk of cardiac failure: insights from the Framingham Study. J Cardiovasc Pharmacol 1987; 10 (Suppl 6): S135–S140.

    PubMed  Google Scholar 

  18. Koren MJ, Devereux RB, Casale PN et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345–52.

    PubMed  CAS  Google Scholar 

  19. Grossman E, Shemesh J, Shamiss A et al. Left ventricular mass in diabetes-hypertension. Arch Intern Med 1992; 152: 1001–4.

    Article  PubMed  CAS  Google Scholar 

  20. Muiesan ML, Salvetti M, Rizzoni D et al. Persistence of left ventricular hypertrophy is a stronger indicator of cardiovascular events than baseline left ventricular mass or systolic performance: 10 years of follow-up. J Hypertens 1996; 14 (Suppl 5): S43–S49.

    CAS  Google Scholar 

  21. Keane WE Proteinuria: its clinical importance and role in progressive renal disease. Am J Kidney Dis 2000; 35 (4 Suppll): S97–105.

    Article  Google Scholar 

  22. Ruilope LM, Campo C, Rodicio JL. Blood pressure control, proteinuria and renal outcome in chronic renal failure. Curr Opin Nephrol Hypertens 1998; 7: 145–8.

    Article  PubMed  CAS  Google Scholar 

  23. Weir MR. Differing effects of antihypertensive agents on urinary albumin excretion. Am J Nephrol 1996; 16: 237–45.

    Article  PubMed  CAS  Google Scholar 

  24. Rodicio JL, Campo C, Ruilope LM. Microalbuminuria in essential hypertension. Kidney Int Suppl 1998; 68: S51–S54.

    Article  PubMed  CAS  Google Scholar 

  25. Oparil S. Treating multiple-risk hypertensive populations. Am J Hypertens 1999; 12: 121S–129S.

    Article  PubMed  CAS  Google Scholar 

  26. Bauer JH. Modern antihypertensive treatment and the progression of renal disease. J Hypertens Suppl 1998; 16: S17–S24.

    PubMed  CAS  Google Scholar 

  27. Kannel WB. High-density lipoproteins: epidemiologic profile and risks of coronary artery disease. Am J Cardiol 1983; 52: 9B–12B

    Article  PubMed  CAS  Google Scholar 

  28. Kaplan NM. Clinical Hypertension. 6th ed. Baltimore: Williams & Wilkins. 1994. Primary hypertension: Pathogenesis; p47–108

    Google Scholar 

  29. Frishman WH, Sonnenblick SH. Cardiovascular Pharmacotherapeutics. New York: McGrawHill publishers; 1997. Alpha-and beta-adrenergic blocking drugs; p 59–94.

    Google Scholar 

  30. Stienen U, Meyer-Sabellek W. Hemodynamic and metabolic effects of carvedilol: a metaanalysis approach. Clin Investig 1992; 70 (Suppll): S65–S72.

    Article  PubMed  Google Scholar 

  31. Moser M, Frishman W. Results of therapy with carvedilol, a beta-blocker vasodilator with antioxidant properties, in hypertensive patients. Am J Hypertens 1998; 11: 15S–15S.

    Article  PubMed  CAS  Google Scholar 

  32. Weber K, Bohmeke T, van der DR, Taylor SH. Hemodynamic differences between metoprolol and carvedilol in hypertensive patients. Am J Hypertens 1998; 11: 614–7.

    Article  PubMed  CAS  Google Scholar 

  33. Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens 1998; 11: 1258–65.

    Article  PubMed  CAS  Google Scholar 

  34. Jacob S, Rett K, Wicklmayr M et al. Differential effect of chronic treatment with two betablocking agents on insulin sensitivity: the carvedilol-metoprolol study [published erratum appears in J Hypertens 1996; 14: 1382]. J Hypertens 1996; 14: 489–94.

    Article  PubMed  CAS  Google Scholar 

  35. Giugliano D, Acampora R, Marfella R et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997; 126: 955–9.

    PubMed  CAS  Google Scholar 

  36. Bristow MR, Gilbert EM, Abraham WT. Effects of carvedilol on LV function and mortality in diabetic versus non-diabetic patients with ischemic or nonischemic dilated cardiomypathy. Circulation 1996; 94 (Suppl I): I–644.

    Article  Google Scholar 

  37. The MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001–7.

    Article  Google Scholar 

  38. CIBIS-II Investigators. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9–13.

    Article  Google Scholar 

  39. Hauf-Zachariou U, Widmann L, Zulsdorf B et al. A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidaemia. Eur J Clin Pharmacol 1993; 45: 95–100.

    Article  PubMed  CAS  Google Scholar 

  40. Gonzalez-Maqueda I. Adrenoreceptors, endothelial function, and lipid profile: effects of atenolol, doxazosin, and carvedilol. Coron Artery Dis 1994; 5: 909–18.

    PubMed  CAS  Google Scholar 

  41. Dupont AG, Van der Niepen P, Taeymans Y et al. Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension. J Cardiovasc Pharmacol 1987; 10 (Suppl II): S130–S136.

    Article  PubMed  Google Scholar 

  42. Abraham W, Tsvetkova T, Lowes BD. Carvedilol improves renal hemodynamics in patients with chronic heart failure. Circulation 1998; 98 (Suppll): I–378–I–379.

    Google Scholar 

  43. Marchi F, Ciriello G. Efficacy of carvedilol in mild to moderate essential hypertension and effects on micro albuminuria: a multicenter, randomized, open-label, controlled study versus atenolol. Adv Ther 1995; 12: 212–21.

    PubMed  CAS  Google Scholar 

  44. Diehm C. Antihypertensive therapy in arterial occlusive disease. Vasa Suppl 1991; 33: 71–4.

    PubMed  CAS  Google Scholar 

  45. Wendt T. Acute hemodynamic effects of carvedilol in comparison with propranolol in patients with coronary heart disease. Clin Investig 1992; 70 (Suppl 1): S93–S97.

    Article  PubMed  Google Scholar 

  46. van der Veur E, ten Berge BS, Wouda AA et al. Effects of atenolol, labetalol and propranolol on the peripheral circulation in hypertensive patients without obstructive vascular disease. Eur J Clin Pharmacol 1985; 28: 131–4.

    Article  PubMed  Google Scholar 

Download references

Authors
  1. W. T. Abraham
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Cardiology, Karolinska Institute, S-171 76, Stockholm, Sweden

    Lars E. Rydén (Professor of Cardiology) (Professor of Cardiology)

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Abraham, W.T. (2001). Anti-Adrenergic Therapy in Hypertensive Patients with Concomitant Disease. In: Rydén, L.E. (eds) Prevention of Disease Progression Throughout the Cardiovascular Continuum. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56525-0_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-56525-0_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-62567-1

  • Online ISBN: 978-3-642-56525-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation